CN114585618A - 含氟嘧啶化合物及其制造方法 - Google Patents

含氟嘧啶化合物及其制造方法 Download PDF

Info

Publication number
CN114585618A
CN114585618A CN202080071319.7A CN202080071319A CN114585618A CN 114585618 A CN114585618 A CN 114585618A CN 202080071319 A CN202080071319 A CN 202080071319A CN 114585618 A CN114585618 A CN 114585618A
Authority
CN
China
Prior art keywords
carbon atoms
hydrocarbon group
general formula
following general
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080071319.7A
Other languages
English (en)
Chinese (zh)
Inventor
清野淳弥
青津理恵
小金敬介
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unimatec Co Ltd
Original Assignee
Unimatec Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unimatec Co Ltd filed Critical Unimatec Co Ltd
Publication of CN114585618A publication Critical patent/CN114585618A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080071319.7A 2019-11-01 2020-10-29 含氟嘧啶化合物及其制造方法 Pending CN114585618A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-199807 2019-11-01
JP2019199807 2019-11-01
PCT/JP2020/040661 WO2021085540A1 (ja) 2019-11-01 2020-10-29 含フッ素ピリミジン化合物およびその製造方法

Publications (1)

Publication Number Publication Date
CN114585618A true CN114585618A (zh) 2022-06-03

Family

ID=75716361

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080071319.7A Pending CN114585618A (zh) 2019-11-01 2020-10-29 含氟嘧啶化合物及其制造方法

Country Status (5)

Country Link
US (1) US12371422B2 (https=)
EP (1) EP4052759A4 (https=)
JP (1) JP7109684B2 (https=)
CN (1) CN114585618A (https=)
WO (1) WO2021085540A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026048597A1 (ja) * 2024-08-27 2026-03-05 ユニマテック株式会社 含フッ素ピリミジン化合物、含フッ素ピリミジノン化合物および殺菌剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3621022A (en) * 1968-01-20 1971-11-16 Boehringer Mannheim Gmbh Antibacterial 5-nitrofuryl-pyrimidines
JPS59104364A (ja) * 1982-12-03 1984-06-16 Nippon Mektron Ltd 新規ピリミジン誘導体およびその製造法
WO1998056789A1 (en) * 1997-06-10 1998-12-17 E.I. Du Pont De Nemours And Company Pyrimidinyl azole herbicides
CN1656195A (zh) * 2002-05-25 2005-08-17 科文有机半导体有限公司 生产高纯三邻位金属化有机铱化合物的方法
CN1871009A (zh) * 2003-09-24 2006-11-29 惠氏控股公司 作为抗癌剂的5－芳基嘧啶
CN104066731A (zh) * 2011-12-27 2014-09-24 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
CN107286146B (zh) 2017-07-05 2020-07-31 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途
CN108299465B (zh) 2018-03-05 2020-01-31 牡丹江医学院 一种治疗胰腺炎的药物及其制备方法
CN108218793B (zh) 2018-04-14 2019-10-11 青岛农业大学 一种含氟嘧啶酮类化合物的合成方法
CN108503623A (zh) 2018-05-11 2018-09-07 四川大学 一种抑制prmt7的化合物及其制备方法与应用
WO2020116296A1 (ja) * 2018-12-07 2020-06-11 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3621022A (en) * 1968-01-20 1971-11-16 Boehringer Mannheim Gmbh Antibacterial 5-nitrofuryl-pyrimidines
JPS59104364A (ja) * 1982-12-03 1984-06-16 Nippon Mektron Ltd 新規ピリミジン誘導体およびその製造法
WO1998056789A1 (en) * 1997-06-10 1998-12-17 E.I. Du Pont De Nemours And Company Pyrimidinyl azole herbicides
CN1656195A (zh) * 2002-05-25 2005-08-17 科文有机半导体有限公司 生产高纯三邻位金属化有机铱化合物的方法
CN1871009A (zh) * 2003-09-24 2006-11-29 惠氏控股公司 作为抗癌剂的5－芳基嘧啶
CN104066731A (zh) * 2011-12-27 2014-09-24 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. P. MOLCHANOV AND R. R. KOSTIKOV: "Product subclass 2: 1-halo-1-(organooxy)alk-1-enes", 《SCIENCE OF SYNTHESIS》, vol. 24, pages 129 - 166 *
YOSHIO INOUYE, ET AL.: "A Facile One-pot Preparation of 2-Methyl- and 2-Phenyl-4- fluoro-5-trifluoromethyl-6-methoxypyrimidine from Methyl Z-hydryl-2-(P-methyl)-F-propyl Ether", 《JOURNAL OF FLUORINE CHEMISTRY》, vol. 27, pages 231 - 236, XP055717031, DOI: 10.1016/S0022-1139(00)84991-X *

Also Published As

Publication number Publication date
US12371422B2 (en) 2025-07-29
WO2021085540A1 (ja) 2021-05-06
JPWO2021085540A1 (https=) 2021-05-06
US20240150329A1 (en) 2024-05-09
EP4052759A4 (en) 2023-12-20
JP7109684B2 (ja) 2022-07-29
EP4052759A1 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
JP6802416B2 (ja) 含フッ素ピリミジン化合物およびその製造方法
US20210087194A1 (en) Chemical Process for Preparing Imidazopyrrolidinone Derivatives and Intermediates Thereof
CN114585618A (zh) 含氟嘧啶化合物及其制造方法
WO2023284058A1 (zh) 一种手性合成尼古丁的制备方法
CN110204474B (zh) 一种合成对四取代nh-吡咯类化合物的方法
JP7614331B2 (ja) 含フッ素ピリミジン化合物およびその製造方法
US12503457B2 (en) Fluorine-containing pyrimidine compound, and method for producing same
JP7159485B2 (ja) 含フッ素ピリミジン化合物およびその製造方法
CN114502551B (zh) 含氟嘧啶化合物及其制备方法
JP7349551B2 (ja) 含フッ素ピリミジン化合物およびその製造方法
WO2021024675A1 (ja) 化合物及びその製造方法
KR101427014B1 (ko) 아릴, 헤테로아릴 혹은 알케닐 치환 불포화 탄화수소류의 제조방법
CN101410386A (zh) 2-链烯基-3-氨基噻吩衍生物及其制备方法
CN115605482A (zh) 含氟稠环嘧啶化合物及其制造方法
WO2024166973A1 (ja) 含フッ素ピラゾロン化合物およびその製造方法
CN118076587A (zh) 含氟吡唑化合物及其制造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination